Antibody

1,020개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,020 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyLimited DatastaleFudan UniversityPhase 2

Vebrekotuzumab (Vebrekotuzumab)

Esophageal Squamous Cell Carcinoma · Esophageal Squamous Cell Carcinoma

#EsophagealSquamousCellCarcinoma#Antibody#Phase2#monoclonal-antibody#Fudan
Trials 1Status Recruiting
AntibodyLimited DatastaleWest China HospitalPhase 2

Vibecotecotamab combined with Putilimab for EGFR-positive refractory biliary malignant tumors (Vibecotecotamab combined with Putilimab for EGFR-positive refractory biliary malignant tumors)

Cancer of Biliary Duct · EGFR

#EGFR#Antibody#Phase2#monoclonal-antibody#CancerofBiliaryDuct+1
Trials 1Status Recruiting
AntibodyLimited DatastaleInflaRx GmbHPhase 2

Vilobelimab (Vilobelimab)

SCC - Squamous Cell Carcinoma of Skin · SCC - Squamous Cell Carcinoma of Skin

#SCC-SquamousCellCarcinomaofSkin#Antibody#Phase2#monoclonal-antibody#InflaRx
Trials 1Status Discontinued
AntibodyLimited DatastaleCatalYm GmbHPhase 2

Visugromab (Visugromab)

Metastatic Non-Squamous Non-Small Cell Lung Cancer; Adult Solid Tumor · Metastatic Non-Squamous Non-Small Cell L

#MetastaticNon-SquamousNon-SmallC#Antibody#Phase2#monoclonal-antibody#AdultSolidTumor+1
Trials 1Status Recruiting
AntibodyLimited DatastaleCatalYm GmbHPhase 2

recommended dose for expansion (Visugromab RDE, Visugromab RDE (recommended dose for expansion))

Metastatic Non-Squamous Non-Small Cell Lung Cancer; Adult Solid Tumor · Metastatic Non-Squamous Non-Small Cell L

#MetastaticNon-SquamousNon-SmallC#Antibody#Phase2#monoclonal-antibody#AdultSolidTumor+1
Trials 1Status Recruiting
AntibodyLimited DatastaleKaty PetersPhase 2

Vorinostst/Bevacizumab/Temozolomide (Vorinostst/Bevacizumab/Temozolomide)

Brain Tumor; Glioblastoma · Brain Tumor

#BrainTumor#Antibody#Phase2#monoclonal-antibody#Glioblastoma+1
Trials 1Status Active
AntibodyLimited DatastaleWigen Biomedicine Technology (S…Phase 2

WJB001 Capsules+Bevacizumab (WJB001 Capsules+Bevacizumab)

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase2#monoclonal-antibody#Wigen
Trials 1Status Recruiting
AntibodyLimited DatastaleFujian Cancer HospitalPreclinical

nivolumab (Opdivo, XBI-302 + Nivolumab)

Gastric Adenocarcinoma; Esophagogastric Junction Adenocarcinoma · Gastric Adenocarcinoma

#GastricAdenocarcinoma#Antibody#Preclinical#monoclonal-antibody#EsophagogastricJunctionAdenocarc+1
Trials 1Status Discontinued
AntibodyLimited DatastaleXencor, Inc.Phase 2

pembrolizumab (Keytruda, XmAb18087 ± Pembrolizumab)

Merkel Cell Carcinoma; Small Cell Lung Cancer · Merkel Cell Carcinoma

#MerkelCellCarcinoma#Antibody#Phase2#monoclonal-antibody#SmallCellLungCancer+1
Trials 1Status Discontinued
AntibodyLimited DatastaleXencor, Inc.Phase 1

XmAb808 (XmAb808)

Ovarian Cancer · Ovarian Cancer

#OvarianCancer#Antibody#Phase1#monoclonal-antibody#Xencor
Trials 1Status Recruiting
AntibodyLimited DatastaleXencor, Inc.Phase 1

XmAb819 (XmAb819)

Clear Cell Renal Cell Carcinoma · Clear Cell Renal Cell Carcinoma

#ClearCellRenalCellCarcinoma#Antibody#Phase1#monoclonal-antibody#Xencor
Trials 1Status Recruiting
AntibodyLimited DatastaleXencor, Inc.Phase 1

XmAb®22841 (XmAb®22841)

Melanoma; Cervical Carcinoma · Melanoma

#Melanoma#Antibody#Phase1#monoclonal-antibody#CervicalCarcinoma+1
Trials 1Status Active
AntibodyLimited DatastaleXencor, Inc.Phase 1

XmAb®23104 (XmAb®23104)

Melanoma (Excluding Uveal Melanoma); Cervical Carcinoma · HER2

#HER2#Antibody#Phase1#monoclonal-antibody#MelanomaExcludingUvealMelanoma+2
Trials 1Status Active
AntibodyLimited DatastaleXencor, Inc.Phase 1

XmAb®808 (XmAb®808)

Head and Neck Squamous Cell Carcinoma; Melanoma Excluding Uveal Melanoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase1#monoclonal-antibody#MelanomaExcludingUvealMelanoma+1
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

Omalizumab (Xolair®, Xolair® (Omalizumab))

Urticaria · Urticaria

#Urticaria#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleCABYCPhase 2

Y-90 Ibritumomab tiuxetan (Y-90 Ibritumomab tiuxetan)

Mantle Cell Lymphoma · Mantle Cell Lymphoma

#MantleCellLymphoma#Antibody#Phase2#monoclonal-antibody#CABYC
Trials 1Status Active
AntibodyLimited DatastaleMediLink Therapeutics (Suzhou) …Phase 2

pembrolizumab (Keytruda, YL242; Pembrolizumab)

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase2#monoclonal-antibody#MediLink
Trials 1Status Recruiting
AntibodyLimited DatastaleBristol Myers SquibbPhase 1

ipilimumab (Yervoy®, Yervoy® (ipilimumab))

Melanoma (Excluding Uveal Melanoma); Cervical Carcinoma · HER2

#HER2#Antibody#Phase1#monoclonal-antibody#MelanomaExcludingUvealMelanoma+2
Trials 1Status Active
AntibodyLimited DatastaleHoffmann-La RochePhase 2

trastuzumab (Herceptin, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1b)

Advanced Solid Tumors; HER2-positive Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#AdvancedSolidTumors+2
Trials 1Status Recruiting
AntibodyLimited DatastaleHoffmann-La RochePhase 2

trastuzumab (Herceptin, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1c)

Advanced Solid Tumors; HER2-positive Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#AdvancedSolidTumors+2
Trials 1Status Recruiting

46 / 51 pages

← PreviousNext →